Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 1427Carcinoma, Renal Cell 587Urinary Bladder Neoplasms 368Kidney Neoplasms 257Carcinoma, Transitional Cell 190Neoplasm Metastasis 163Neoplasms 124Melanoma 83Breast Neoplasms 80Carcinoma, Non-Small-Cell Lung 78Testicular Neoplasms 67Ovarian Neoplasms 62Sarcoma 55Urethral Neoplasms 51Non-Muscle Invasive Bladder Neoplasms 51Wilms Tumor 49Lung Neoplasms 45Colorectal Neoplasms 44Uterine Cervical Neoplasms 39Neuroblastoma 39Penile Neoplasms 37Pancreatic Neoplasms 37Urologic Neoplasms 34Recurrence 32Lymphoma, Non-Hodgkin 32Ureteral Neoplasms 28Osteosarcoma 28Testicular Germ Cell Tumor 26Small Cell Lung Carcinoma 26Head and Neck Neoplasms 26

Interventions

Androgen Antagonists 2relugolix 1niraparib 1Prednisone 1Docetaxel 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Metastatic Hormone-sensitive Prostate Cancer (mHSPC) × Genitourinary × Clear all
NCT06392841 2026-04-08

HARMONY

Hoosier Cancer Research Network

Phase 2 Withdrawn
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT07216248 2025-10-29

OPTIMAS

University of Utah

Phase 2 Recruiting
160 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡